Multiparametric MRI-based fusion radiomics for predicting telomerase reverse transcriptase (TERT) promoter mutations and progression-free survival in glioblastoma: a multicentre study.

Purpose: This study evaluated the performance of multiparametric magnetic resonance imaging (MRI)–based fusion radiomics models (MMFRs) to predict telomerase reverse transcriptase (TERT) promoter mutation status and progression-free survival (PFS) in glioblastoma patients. Methods: We retrospectivel...

Descripción completa

Detalles Bibliográficos
Publicado en:Neuroradiology Vol. 66; no. 1; pp. 81 - 93
Autores principales: Zhang, Hongbo, Zhang, Hanwen, Zhang, Yuze, Zhou, Beibei, Wu, Lei, Yang, Wanqun, Lei, Yi, Huang, Biao
Formato: research tables/charts Journal Article
Publicado: Springer Nature Jan2024
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=174559450&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 174559450
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        00283940
        NYZ
      jtl: Neuroradiology
      issn: 00283940
      maglogo: N
    pubinfo:
      dt: Jan2024
      vid: 66
      iid: 1
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        174559450
        173652333
        174559450
        174559450
        10.1007/s00234-023-03245-3
        174559450
      ppf: 81
      ppct: 12
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Multiparametric MRI-based fusion radiomics for predicting telomerase reverse transcriptase (TERT) promoter mutations and progression-free survival in glioblastoma: a multicentre study.
      aug:
        au:
          Zhang, Hongbo
          Zhang, Hanwen
          Zhang, Yuze
          Zhou, Beibei
          Wu, Lei
          Yang, Wanqun
          Lei, Yi
          Huang, Biao
        affil: https://ror.org/01vjw4z39 The Second School of Clinical Medicine, Southern Medical University, 510515, Guangzhou, China
      sug:
        subj:
          Glioma Prognosis
          Glioma Therapy
          Radiomics Methods
          Magnetic Resonance Imaging Methods
          Telomerase Analysis
          Mutation
          Prediction Models
          Outcome Assessment
          Human
          Multicenter Studies
          Retrospective Design
          Record Review
          Internal Validity
          Cancer Patients
          Cancer Care Facilities
          Progression-Free Survival
          Confidence Intervals
          Descriptive Statistics
          Temozolomide Therapeutic Use
          Glioma Surgery
          Glioma Drug Therapy
          Postoperative Care Methods
          Chemotherapy, Cancer Methods
      ab: Purpose: This study evaluated the performance of multiparametric magnetic resonance imaging (MRI)–based fusion radiomics models (MMFRs) to predict telomerase reverse transcriptase (TERT) promoter mutation status and progression-free survival (PFS) in glioblastoma patients. Methods: We retrospectively analysed 208 glioblastoma patients from two hospitals. Quantitative imaging features were extracted from each patient's T1-weighted, T1-weighted contrast-enhanced, and T2-weighted preoperative images. Using a coarse-to-fine feature selection strategy, four radiomics signature models were constructed based on the three MRI sequences and their combination for TERT promoter mutation status and PFS; model performance was subsequently evaluated. Subgroup analyses were performed by the radiomics signature of TERT promoter mutation status and PFS to distinguish patients who could benefit from prolonged temozolomide chemotherapy cycles. Results: TERT promoter mutation status was best predicted by MMFR, with an area under the curve (AUC) of 0.816 and 0.812 for the training and internal validation sets, respectively. The external test set also achieved stable and optimal prediction results (AUC, 0.823). MMFR better predicted patient PFS compared with the single-sequence radiomics signature in the test set (C-index, 0.643 vs 0.561 vs 0.620 vs 0.628). Subgroup analyses showed that more than six cycles of postoperative temozolomide chemotherapy were associated with improved PFS for patients in class 2 (high TERT promoter mutation and high survival rates; HR, 0.222; 95% CI, 0.054 − 0.923; p = 0.025). Conclusion: MMFR is an effective method to predict TERT promoter mutations and PFS in patients with glioblastoma. Moreover, subgroup analysis could differentiate patients who may benefit from prolonged TMZ chemotherapy cycles.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N